Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Topol departs Cleveland Clinic

Executive Summary

Eric Topol, an outspoken critic of COX-2 inhibitors and a witness in Vioxx product liability cases, resigns from his position as chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic. Topol will join the Department of Genetics at Case Western University. He will continue to work with the Cleveland Clinic as a consultant and serve as program director of an NIH grant in collaboration with the clinic. A study of Pfizer's COX-2 Celebrex will be conducted at the Cleveland Clinic under the direction of Steven Nissen (1"The Pink Sheet" Dec. 19, 2005, p. 18)...

You may also be interested in...

Topol to Scripps

Former Cleveland Clinical Department of Cardiovascular Medicine Chair Eric Topol will lead new Scripps Translational Science Institute. Topol will serve as chief academic officer and chief of genomic medicine and translational sciences, as well as a senior consultant in the San Diego-based healthcare system's cardiology division. Topol left the Cleveland Clinic in February after 15 years heading its cardio program (1"The Pink Sheet" Feb. 13, 2006, In Brief)...

Nissen fills Topol’s shoes

Medical Director of the Cleveland Clinic's Cardiovascular Coordinating Center Steven Nissen is named interim chairman of the hospital's Department of Cardiovascular Medicine, effective immediately. Nissen replaces Eric Topol, who recently resigned (1"The Pink Sheet" Feb. 13, 2006, In Brief). A search committee will soon begin interviewing and considering external and internal candidates - including Nissen - to permanently fill the position. Nissen, who joined the Cleveland Clinic in 1992, has served as vice-chairman of the cardiology department, section head of clinical cardiology and director of the coronary intensive care unit...

Celebrex Heart Risk To Be Assessed By Cleveland Clinic In Pfizer-Funded Study

Pfizer's support for a massive study of Celebrex safety brings the drug maker together with researchers who have been urging the company to conduct additional trials; Pfizer approached Cleveland Clinic cardiovascular researchers about conducting the trial, which was announced Dec. 13




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts